- Teva Pharmaceutical Industries (NYSE:TEVA +0.5%) announces its U.S. commercial launch of a generic equivalent to ViiV Healthcare's Epzicom (abacavir and lamivudine) tablets, 600 mg/300 mg. It is indicated, in combination with other antiretroviral agents, for the treatment of HIV-1 infection.
- According to IMS, the U.S. market for the branded product is ~$450M.
- ViiV Healthcare is the HIV-focused company formed by GlaxoSmithKline (GSK +0.9%) and Pfizer (PFE +0.1%).
Teva launches generic Epzicom in U.S.
Recommended For You
About TEVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TEVA | - | - |
Teva Pharmaceutical Industries Limited |